Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer
Decision Resources
April 9, 2009 33 Pages - SKU: DECR2219112
|
|
Introduction
Targeted cancer therapies have achieved phenomenal growth, and many MAb-based immunotherapies are blockbusters
or mega-blockbusters. This market success is due not only to these MAbs' ability to treat unmet need in
many cancers but also to the high cost of immunotherapies and biologics in general. Competition is increasing as
more companies move into this arena; also, biosimilars will soon enter markets. Meanwhile, the cancer vaccine
market is signifi cantly behind the MAb-based market in terms of products on the market, a robust pipeline, and
workable technologies, but researchers hold out hope for the eventual success of this emerging market segment.
Get the Answers You Need to Shape Your Strategy
- Eli Lilly's CEO John Lechleiter told investors that oncology is going to be a sustainable play for many years to come.
What is the outlook for the oncology market? Why are new companies fl ooding targeted therapy markets?
- Companies are looking to gain a foothold in biologics markets or to extend MAb franchises. What types of therapeutic
cancer MAb deals have taken place in the last two years? What strategies are companies using?
- The emerging cancer vaccine market is signifi cantly behind the therapeutic cancer MAb market. What is the key issue
involved in developing cancer vaccines? What technologies are in development? What deals are being made?
- Bristol-Myers Squibb's CEO James M. Cornelius told investors that an ImClone acquisition was the next logical step
in the company's almost ten-year relationship with ImClone. Why did BMS want to acquire ImClone? What key
factor played in Lilly's successful bid and acquisition of ImClone?
- Roche has transitioned its pharmaceutical business with a focus on specialty segments and biologics. What was
involved in Roche's eight-month struggle to take over Genentech? Why was the winning bid agreeable to both
parties?
- Schering-Plough's CEO Fred Hassan said stunning and accelerating changes in the global macro environment are driving
changes in the pharma industry. Why did Schering-Plough accept Merck & Co.'s offer for a reverse merger?
What technologies were key to the merger strategy?
Scope
- Therapeutic monoclonal antibodies: Late-stage pipeline, targets, gold standards, combination MAb therapies, engineered/
optimized antibodies, next-generation antibodies, biosimilar market entry dates, patent expiry.
- Cancer vaccines: Late-stage pipeline, marketed vaccines, vaccine technologies, troubled companies.
- Biosimilars: Patent expiry, market entry dates, companies facing signifi cant challenges, big pharmaceutical
companies moving into this market.
- Dealmaking trends and opportunities: Antibody-based deals, three therapeutic MAb-related mergers and
acquisitions involving Big Pharma, six cancer vaccine deals involving Big Pharma.
- Market drivers: Indication expansion, cost, early-stage disease, biomarkers, biosimilars, combination
therapies, evolving technologies, survey of oncologists and managed care organization pharmacy directors,
formulary coverage of therapeutic cancer MAbs, Decision Resources' Drug Comparator Model.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
|
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Oncology Markets
- Therapeutic Cancer Antibodies
- Antibodies Already on the Market
- Antibodies in Late-Stage Development
- Cancer Vaccines
- Vaccine Technologies
- Clinical Development Pipeline
- Industry-Shaping Events
- Combination MAb Therapies Not As Obvious As Hoped
- Some Cancer Vaccine Companies on the Brink
- Recent Deals and Business Strategies
- Antibody-Based Dealmaking
- Lilly’s Acquisition of ImClone Systems
- Roche’s Hostile Takeover of Genentech
- Merck & Co.’s Planned Merger with Schering-Plough
- Cancer Vaccine Dealmaking
- GlaxoSmithKline and Innogenetics
- Pfi zer and Celldex Therapeutics
- Merck Serono and Oncothyreon
- Takeda and Cell Genesys
- Oxford BioMedica and Sanofi -Aventis
- Transgene and Roche
- Market Drivers—MAb-Based Immunotherapies
- Additional Indications
- Shifts to Earlier-Stage Disease
- Biomarkers
- Biosimilars
- Cost
- Combination Targeted Therapies
- Market Drivers—Cancer Vaccines
- Outlook
- Tables
- 1. Marketed Antibody Therapies for Oncology
- 2. Select Antibody Therapies in Phase II or Phase III Development for Oncology
- 3. Cancer Vaccines in Phase III Development or Later
- 4. Select Combination Targeted Therapies in Development, 2008
- 5. Dealmaking: Cancer Monoclonal Antibodies, 2007 and 2008
- 6. Dealmaking: Select Cancer Vaccines, 2008
- 7. Dealmaking: Biomarkers Driving the Development and Sale of Targeted Cancer Therapies, 2008
- 8. Potential Biosimilar Entry Dates for Marketed Monoclonal Antibody-Based Immunotherapies
- 9. Cost Comparison of Targeted Therapy Cancer Treatment in the Adjuvant and Advanced-Stage Settings
- Figures
- 1. Forecasted Growth Rate for the Oncology Market, 2007-2014
- 2. Top Ten Companies in the Oncology Market, 2007 and 2014
- 3. Targeted Monoclonal Antibody Therapies: Combined Treatment in Metastatic Colorectal Cancer
- 4. Commercial Potential of Treating Early-Stage and Late-Stage Cancer
Share this report
Other tasks Related Markets Oncology/Hematology Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
